Phoenix PharmaLabs is a pre-clinical stage drug development company focused on the development and commercialization of non-addictive treatments for pain and therapies for the treatment of opiate addiction. The Company offers a novel family of ligands with a high binding affinity at three opiate receptors: mu, kappa, and delta.